- Home
- PET vs LPCN Comparison
PET vs LPCN Comparison
Compare PET & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PET
- LPCN
- Stock Information
- Founded
- PET 2015
- LPCN 1997
- Country
- PET United States
- LPCN United States
- Employees
- PET N/A
- LPCN N/A
- Industry
- PET EDP Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- PET Technology
- LPCN Health Care
- Exchange
- PET Nasdaq
- LPCN Nasdaq
- Market Cap
- PET 40.1M
- LPCN 36.8M
- IPO Year
- PET N/A
- LPCN N/A
- Fundamental
- Price
- PET $0.21
- LPCN $4.66
- Analyst Decision
- PET Strong Buy
- LPCN Strong Buy
- Analyst Count
- PET 5
- LPCN 1
- Target Price
- PET $4.40
- LPCN $10.00
- AVG Volume (30 Days)
- PET 1.3M
- LPCN 28.3K
- Earning Date
- PET 11-13-2024
- LPCN 11-07-2024
- Dividend Yield
- PET N/A
- LPCN N/A
- EPS Growth
- PET N/A
- LPCN N/A
- EPS
- PET N/A
- LPCN N/A
- Revenue
- PET $76,747,000.00
- LPCN $7,922,926.00
- Revenue This Year
- PET $9.11
- LPCN N/A
- Revenue Next Year
- PET $14.58
- LPCN N/A
- P/E Ratio
- PET N/A
- LPCN N/A
- Revenue Growth
- PET N/A
- LPCN N/A
- 52 Week Low
- PET $0.14
- LPCN $2.38
- 52 Week High
- PET $2.47
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- PET 19.16
- LPCN 40.47
- Support Level
- PET $0.14
- LPCN $4.63
- Resistance Level
- PET $0.18
- LPCN $5.40
- Average True Range (ATR)
- PET 0.07
- LPCN 0.54
- MACD
- PET -0.04
- LPCN -0.13
- Stochastic Oscillator
- PET 11.35
- LPCN 2.20
About PET Wag! Group Co.
Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools, and pet wellness plans.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.